Valuation: ProSomnus, Inc.

Market Cap 237K 205K 191K 176K 331K 22.58M 337K 2.26M 884K 11.22M 888K 869K 37.72M P/E 2022
-7.8x
P/E 2023 -0.66x
Enterprise Value 35.24M 30.61M 28.43M 26.22M 49.38M 3.36B 50.28M 337M 132M 1.67B 132M 129M 5.62B EV / Sales 2022
5.49x
EV / Sales 2023 1.85x
Free-Float
90.18%
Yield 2022 *
-
Yield 2023 -
3 years 0
Extreme 0.004
2.09
5 years 0
Extreme 0.004
11.3
10 years 0
Extreme 0.004
11.3
Manager TitleAgeSince
Chief Executive Officer 52 03/05/2022
Chief Tech/Sci/R&D Officer 45 03/05/2022
Director of Finance/CFO 57 01/03/2023
Date Insider Type Main position Quantity % Market Cap.
15/02/24 Free

Founder

315,742 1.9254%
15/02/24 Free

Chief Financial Officer

315,742 1.9254%
15/02/24 Free

Chief Executive Officer

1,322,756 8.0663%
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--%-.--%-99.34% 237K
-2.74%+10.60%-14.99%+15.39% 4.02B
+1.76%+7.32%+38.87% - 1.33B
-0.51%+8.35%+18.23% - 673M
-0.77%-0.77%-11.64%-3.19% 149M
-4.71%-18.93%+24.66%+17.42% 97.16M
Average -1.16%+1.27%+9.19%-17.43% 1.05B
Weighted average by Cap. -1.53%+12.03%+0.71%+14.78%

Financials

2022 2023
Net sales 19.39M 16.85M 15.64M 14.43M 27.17M 1.85B 27.67M 185M 72.51M 920M 72.83M 71.23M 3.09B 27.65M 24.02M 22.3M 20.57M 38.75M 2.64B 39.45M 264M 103M 1.31B 104M 102M 4.41B
Net income -7.15M -6.21M -5.76M -5.32M -10.01M -682M -10.19M -68.23M -26.72M -339M -26.83M -26.25M -1.14B -24.1M -20.93M -19.44M -17.92M -33.76M -2.3B -34.37M -230M -90.09M -1.14B -90.48M -88.5M -3.84B
Net Debt 17.17M 14.91M 13.85M 12.77M 24.05M 1.64B 24.49M 164M 64.18M 814M 64.46M 63.05M 2.74B 35.01M 30.41M 28.24M 26.04M 49.05M 3.34B 49.94M 334M 131M 1.66B 131M 129M 5.58B
Logo ProSomnus, Inc.
ProSomnus, Inc. is a medical technology company. The Company is focused on the development, manufacturing and marketing of precision intraoral medical devices, a novel non-invasive option for treating and managing patients with obstructive sleep apnea (OSA). Its intraoral medical devices are engineered to precisely track the treatment plan and anatomy for each patient. The Company's devices have demonstrated efficacy, safety, adherence, and overall outcomes in a growing body of clinical investigations. Its precision intraoral devices are FDA-cleared, patented, and covered by commercial medical insurance, Medicare, TRICARE and many Government-sponsored healthcare plans around the world, representing over 200 million covered lives. The Company’s products include ProSomnus EVO Sleep and Snore Device, ProSomnus EVO SELECT Sleep and Snore Device, ProSomnus EVO [PH] Sleep and Snore Device, ProSomnus [CA] LP Sleep and Snore Device and ProSomnus [MOG] Morning Occlusal Guide.
Employees
136
  1. Stock Market
  2. Stocks
  3. LAAA Stock